Merck's Keytruda wins melanoma OK in Europe; Pfizer plots R&D base in Cambridge, MA; Abbott's generic sales shine;

@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce

> Merck & Co.'s ($MRK) Keytruda nabbed European approval for use in advanced melanoma patients, both previously untreated and previously treated, in the ongoing push for market share in cancer immunotherapies. Release

> Pfizer ($PFE) is expanding its R&D presence in Cambridge, MA, with plans to put 1,000 staffers in the biotech hub around Kendall Square. Report

> Abbott Laboratories ($ABT) beat second-quarter profit estimates, partly because of strong generic drug sales, which rose 31% on a buyout of Chile's CFR Pharmaceuticals last year. Report

> GlaxoSmithKline ($GSK) sued Tibco Software, claiming the California-based company used its proprietary information to develop a risk-based monitoring tool that it's now selling as a custom software package. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev

@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce

> iHealth expands its retail, connected medical device empire and looks to move into corporations, hospitals. Article

> Propeller Health receives FDA clearance to sell its app and sensor to patients using Glaxo's inhalers. More

> Bloomberg: St. Jude Medical discussing takeover of Thoratec. Report

Biotech News

@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech

@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce

@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce

> AstraZeneca's once-lauded drug flunks a Phase III eye cancer trial. More

> Xoma crushed as lead drug flunks a PhIII challenge. Article

> In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study. Story

> Roche brings an Alzheimer's drug back from the brink with another PhIII endeavor. News

> Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's. Report

Biotech Research News

> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report

> Animal study highlights role of mast cells in chronic eye diseases. More

> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report

> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story

> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article

Diagnostics News

> Illumina launches new lab service for HiSeq X sequencing systems. More

> Alere revs up engine with new deals and win for quick strep test. Story

> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News

> Oxford Nanopore reels in $109M to ramp up R&D. Item

> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article

Pharma Marketing News

> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More

> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item

> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report

> What's in a pill color? Consumers see messages in red, blue, green and white. Story

> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article

And Finally... More than one in 5 sexually active teen girls have used the morning-after pill, in a dramatic increase that may reflect that it's now easier for them to buy the emergency contraceptive, the AP reports. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.